InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,090.62
(
-0.15%
)
Post# of 252199
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

bellweather1

Send PM Follow Ignore
Followers 11
Posts 2370
Boards Moderated 0
Alias Born 06/08/2010

bellweather1

Re: DewDiligence post# 175475

Thursday, 03/13/2014 5:04:31 PM

Thursday, March 13, 2014 5:04:31 PM

Post# of 252199
TGTX-

TG-1101 doesn't appear to be that similar to Rituxin-same class, but unique epitope on CD20.

Also, like Gazyva, glycoengineered(meaning sugar residues that limited signal potentcy in earlier generation CD20s are minimized)-result:50-100X the ADCC of Rituxin.

The results of this, in a small study in R/R Clls Pts(pg11 of slides below) was 100% peripheral(blood) response, and 63.6% (nodal) partial responses at 4 months, vs a 13% response rate in comparable pts on Rituxin. Quit different.


http://files.shareholder.com/downloads/MHA/3008734518x0x719982/c0400996-8b4b-45bb-9149-4ba72fab36f3/TG_Therapeutics_Corporate_Presentaton_JPM_2014_jb.pdf
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up